Buy Ciclib PALBOCICLIB

Ciclib 125mg capsules contain palbociclib, a cyclin-dependent kinase inhibitor used in cancer therapy. These oral capsules support treatment regimens for hormone receptor-positive breast cancer. Suitable for ambient storage, they provide a convenient oral option for chemotherapy support.

Strength

125mg

Pack Size

21S

Storage

Ambient

Manufacturer / TM Owner

Shilpa Medicare

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Uses / Indications

Ciclib 125mg capsules are used to treat certain types of breast cancer, particularly hormone receptor-positive cases. They work by inhibiting cyclin-dependent kinases to slow cancer cell growth. Often prescribed alongside hormone therapy, they help manage advanced or metastatic breast cancer in adults.

Side Effects

Ciclib 125mg capsules may cause temporary changes in blood cell counts, leading to increased infection risk or fatigue. Some users report mild nausea, diarrhea, or hair thinning during treatment. Appetite changes and mouth sores are also reported by a small number of patients.

Precautions & Warnings

Store Ciclib 125mg capsules at room temperature away from moisture and heat. Keep out of reach of children and pets. Avoid crushing or opening capsules; swallow whole with water. Report any signs of infection, unusual bleeding, or severe fatigue to a healthcare provider promptly.

Avoid Interactions

Ciclib 125mg may interact with strong CYP3A inhibitors or inducers, altering drug levels in the body. Grapefruit products can increase palbociclib levels, potentially raising side effect risks. Hormonal therapies and certain antibiotics may also interact; consult a healthcare professional before combining medications.

References

Frequently Asked Questions

Ciclib 125mg capsules are used to treat hormone receptor-positive breast cancer in adults, often in combination with hormone therapy.

Take Ciclib 125mg capsules whole with water, as directed by your doctor. Do not crush, chew, or open the capsules.

Common side effects include fatigue, nausea, diarrhea, and changes in blood cell counts. Some users experience hair thinning or mouth sores.

Avoid grapefruit or grapefruit juice while taking Ciclib 125mg, as it may increase the risk of side effects.

Ciclib 125mg contains palbociclib, which is a targeted therapy used alongside chemotherapy or hormone therapy for breast cancer.

Published by GNH India Pharmaceuticals Limited

Last updated: 18 May 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.